Literature DB >> 32566028

Expression of ASAP1 and FAK in gastric cancer and its clinicopathological significance.

Qiong Luo1, Suyun Zhang1, Donghuan Zhang1, Fang Yuan2, Xiangqi Chen2, Sheng Yang1.   

Abstract

The present study aimed to analyze the expression levels of adenosine diphosphate ribosylation factor guanylate kinase 1 (ASAP1) and focal adhesion kinase (FAK) in gastric cancer (GC) tissues in order to explore their association with clinicopathological features and prognosis. A total of 32 patients with GC were enrolled in the present study. All patients had complete clinical follow-up data and paraffin-embedded normal gastric mucosal tissues. The expression levels of ASAP1 and FAK in these tissues were measured by immunohistochemistry. The associations of ASAP1 and FAK expression with clinicopathological factors and the survival of patients with GC were subsequently analyzed. The expression levels of ASAP1 (59.4%) and FAK (68.8%) in GC tissues were significantly higher than those in normal gastric mucosal tissues (28.1 and 40.6%, P<0.05). The expression levels of ASAP1 and FAK were associated with depth of invasion, lymph node metastasis and pathological stage (P<0.05). ASAP1 expression was positively associated with FAK expression (P<0.001). In addition, ASAP1 and FAK expression levels were negatively associated with disease-free survival time and overall survival time (P<0.05). The 5-year overall survival rate was significantly higher in patients with negative ASAP1 or FAK expression compared with that in patients with positive ASAP1 or FAK expression (P<0.05). In conclusion, ASAP1 and FAK were highly expressed in human GC tissues and may serve a synergistic role in promoting tumorigenesis, progression, invasion and metastasis in patients with GC. ASAP1 and FAK expression in GC were associated with patient's survival. Therefore, ASAP1 and FAK may represent novel molecular markers for the pathophysiology and prognosis of GC.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  adenosine diphosphate ribosylation factor guanylate kinase 1; focal adhesion kinase; gastric cancer; prognosis

Year:  2020        PMID: 32566028      PMCID: PMC7285715          DOI: 10.3892/ol.2020.11612

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  4 in total

1.  Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma.

Authors:  Mohd Altaf Najar; Mohammad Arefian; David Sidransky; Harsha Gowda; T S Keshava Prasad; Prashant Kumar Modi; Aditi Chatterjee
Journal:  Front Genet       Date:  2022-05-13       Impact factor: 4.772

2.  FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways.

Authors:  Xueyun Huo; Wenjing Zhang; Guannan Zhao; Zhenwen Chen; Peixin Dong; Hidemichi Watari; Ramesh Narayanan; Todd D Tillmanns; Lawrence M Pfeffer; Junming Yue
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

3.  ptk2 and mt2a Genes Expression in Gastritis and Gastric Cancer Patients with Helicobacter pylori Infection.

Authors:  Manouchehr Ahmadi Hedayati; Delniya Khani; Farshad Sheikhesmaeili; Bijan Nouri
Journal:  Can J Gastroenterol Hepatol       Date:  2022-08-25

4.  Clinicopathological Implications of ASAP1 Expression in Hepatocellular Carcinoma.

Authors:  Seongsik Bang; Seungyun Jee; Hwangkyu Son; Hyebin Cha; Jongmin Sim; Yeseul Kim; Hosub Park; Jaekyung Myung; Hyunsung Kim; Seungsam Paik
Journal:  Pathol Oncol Res       Date:  2022-08-30       Impact factor: 2.874

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.